Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT02324491 Org: User:
Start: 12/31/14 End: 12/31/15 Due: 12/31/16

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Phase: N/A Priority: Normal
NCT ID: NCT02063295 Org: User:
Start: 04/30/14 End: 11/30/14 Due: 11/30/15

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01818921 Org: User:
Start: 06/30/13 End: 11/30/13 Due: 11/30/14

An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01666691 Org: User:
Start: 08/31/12 End: 05/31/13 Due: 05/31/14

ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

Phase: N/A Priority: Normal
NCT ID: NCT01507077 Org: User:
Start: 12/31/11 End: 03/31/12 Due: 03/31/13

Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01028261 Org: User:
Start: 12/31/09 End: 10/31/10 Due: 10/31/11

Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01372761 Org: User:
Start: 06/30/11 End: 11/30/11 Due: 11/30/12

Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT03254368 Org: User:
Start: 09/12/17 End: 02/22/19 Due: 02/22/20

Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02179151 Org: User:
Start: 09/30/14 End: 10/31/16 Due: 10/31/17